The Common H202D Variant in GDF-15 Does Not Affect Its Bioactivity but Can Significantly Interfere with Measurement of Its Circulating Levels.

Saved in:
Bibliographic Details
Title: The Common H202D Variant in GDF-15 Does Not Affect Its Bioactivity but Can Significantly Interfere with Measurement of Its Circulating Levels.
Authors: Karusheva Y; MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.; Department of Clinical Biochemistry, NIHR Cambridge Biomedical Research Centre, Cambridge, UK., Ratcliff M; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.; Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK., Mörseburg A; MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.; Department of Clinical Biochemistry, NIHR Cambridge Biomedical Research Centre, Cambridge, UK., Barker P; Department of Clinical Biochemistry, NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Core Biochemical Assay Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK., Melvin A; MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.; Department of Clinical Biochemistry, NIHR Cambridge Biomedical Research Centre, Cambridge, UK., Sattar N; British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA, UK., Burling K; Department of Clinical Biochemistry, NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK., Backmark A; Discovery Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Roth R; Discovery Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Jermutus L; Projects, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Guiu-Jurado E; Department for Clinical Obesity Research, Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany., Blüher M; Department for Clinical Obesity Research, Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany., Welsh P; British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA, UK., Hyvönen M; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK., O'Rahilly S; MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.; Department of Clinical Biochemistry, NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
Source: The journal of applied laboratory medicine [J Appl Lab Med] 2022 Oct 29; Vol. 7 (6), pp. 1388-1400.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101693884 Publication Model: Print Cited Medium: Print ISSN: 2576-9456 (Print) Linking ISSN: 24757241 NLM ISO Abbreviation: J Appl Lab Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2576-9456
DOI:10.1093/jalm/jfac055